Blood Cancer Therapeutics: Global Markets to 2030

Description

List of Tables

The global market for blood cancer therapeutics was valued at $77.1 billion in 2025 and is projected to reach $125.5 billion by the end of 2030, at a compound annual growth rate (CAGR) of 10.2% from 2025 to 2030.

Report Scope

This report analyzes market trends for blood cancer therapeutics, providing data from 2024, 2025 estimates, compound annual growth rate projections through 2030 (forecast period: 2025-2030), and regional markets. It covers the market potential, competitive environment, regulatory scenarios, drivers, restraints, and opportunities, as well as market projections for 2030 and market share for key companies.

The market scope in this report is segmented by type into leukemia, lymphoma, multiple myeloma, and rare blood disorders. Leukemia is further subdivided into acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myelogenous (myeloid) leukemia (AML), and chronic myelogenous (myeloid) leukemia (CML). Lymphoma is further subdivided into non-Hodgkin lymphoma and Hodgkin lymphoma. Rare blood disorders include myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs).

The market has been segmented into significant geographies: North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The regional segment will provide a detailed analysis of major countries, including the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China, South Korea, Australia, and India. For market estimates, data will be provided for 2024 as the base year, with forecasts for 2025 and a 2030 forecast value.

The report aims to:

Analyze types of blood cancer therapeutics.
Analyze global market size and segmentation.
Understand market constraints and drivers.
Provide detailed market forecasts for 2030.
Assess market shares, competitiveness, and industry structure.
Identify potential long-term impacts on the blood cancer therapeutics market.

Report Includes

88 data tables and 63 additional tables
An overview and analysis of the global blood cancer therapeutics market
Analyses of global market trends, with revenue data for 2024, estimates for 2025, and projections of CAGRs through 2030
Estimates of the current market size and growth prospects, with a market share analysis by cancer type, therapeutic class, and region
Facts and figures related to market dynamics, including key drivers, restraints, challenges, and opportunities
Review of macroeconomic factors and insights derived from Porter's Five Forces analysis
Overview of the regulatory landscape across North America, Europe, and Asia-Pacific
Discussion of emerging technologies and developments, including clinical trials, pipeline analysis, and patent activity
Detailed market analysis by blood cancer type, including leukemia, lymphoma, and multiple myeloma
Regional market analysis covering North America, Europe, Asia-Pacific, the Middle East and Africa, and South America, with country-level data
Analysis of the competitive landscape, including company share analysis and strategic initiatives
Company profiles of major players within the industry, including Johnson & Johnson, Bristol-Myers Squibb Co., AbbVie Inc., Novartis AG, and F. Hoffmann-La Roche Ltd.

Product Code: PHM210B

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion

Chapter 2 Market Overview

Overview
Macroeconomic Factor Analysis
Impact of U.S. Tariffs on the Pharmaceutical Industry
Healthcare Expenditure
Impact of Global Economic Growth (GDP) on the Pharma Sector
Porter's Five Forces Analysis
Bargaining Power of Buyers
Bargaining Power of Suppliers
Potential for New Entrants
Threat of Substitutes
Competitiveness in the Industry

Chapter 3 Market Dynamics

Market Dynamics
Market Drivers
Rise in Blood Cancer Cases
Increasing Burden of Blood Cancers
Rising R&D Investment Among Companies in the Market
Increase in Government Funding and Pharmaceutical R&D Expenditures
Market Restraints
Rising Generic Competition and Patent Expiration
Availability of Affordable Chemotherapeutics Restricts Growth of Advanced Therapies
High Cost of Blood Cancer Therapeutics
Market Opportunities
Potential of Blood Cancer Therapeutics
Emerging Markets
Technological Advances in Drug Manufacturing

Chapter 4 Regulatory Landscape

Overview
U.S.
Europe
Asia-Pacific

Chapter 5 Emerging Technologies and Pipeline Analysis

Overview
Artificial Intelligence (AI)
Antibody-Modified Nanosystems
Targeted Drug Delivery
Clinical Trial Analysis
Clinical Trials Analysis by Type of Study
Clinical Trials Analysis by Status
Clinical Trials Analysis by Phase
Key Takeaways
Patent Analysis
Key Takeaways

Chapter 6 Market Segmentation Analysis

Segmentation Breakdown
Global Market for Blood Cancer Therapeutics, by Cancer Type
Key Takeaways
Lymphoma
Leukemia
Multiple Myeloma
Rare Blood Cancers
Global Market for Blood Cancer Therapeutics, by Therapeutic Type
Key Takeaways
Targeted Therapy
Immunotherapy
Chemotherapy
Geographic Breakdown
Global Market for Blood Cancer Therapeutics, by Region
Key Takeaways
North America
Europe
Asia-Pacific
Middle East and Africa
Middle East
South America

Chapter 7 Competitive Intelligence

Key Takeaways
Competitive Landscape
Company Share Analysis

Chapter 8 Appendix

Methodology
Abbreviations
Sources
Company Profiles
ABBVIE INC.
AMGEN INC.
AMNEAL PHARMACEUTICALS LLC.
ASTRAZENECA
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
GSK PLC.
JAZZ PHARMACEUTICALS INC.
JOHNSON & JOHNSON
LILLY USA LLC
MERCK & CO. INC.
NOVARTIS AG
REGENERON PHARMACEUTICALS INC.
SANOFI

Product Code: PHM210B

List of Tables

Summary Table : Global Market for Blood Cancer Therapeutics, by Region, Through 2030
Table 1 : Current Health Expenditure, by Country, 2021-2023
Table 2 : Projected Leukemia Cases, by Region, Through 2035
Table 3 : Projected Hodgkin Lymphoma Cases, by Region, Through 2035
Table 4 : Projected Non-Hodgkin Lymphoma Cases, by Region, Through 2035
Table 5 : Projected Multiple Myeloma Cases, by Region, Through 2035
Table 6 : National Cancer Institute Funding, by Mechanism, 2020-2024
Table 7 : Few Approved Biosimilars in the Market for Blood Cancer
Table 8 : Average Price of a Blood Cancer Therapeutic
Table 9 : Clinical Trials in Blood Cancer Therapeutics, by Type of Study, as of January 2026
Table 10 : Clinical Trials in Blood Cancer Therapeutics, by Status, as of January 2026
Table 11 : Clinical Trials in Blood Cancer Therapeutics, by Phase, as of January 2026
Table 12 : List of Selected Blood Cancer Clinical Trials in Phase IV
Table 13 : List of Selected Recent Patents Related to Blood Cancer, 2026
Table 14 : Global Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
Table 15 : Subtypes of Non-Hodgkin Lymphoma, by Type
Table 16 : Subtypes of Hodgkin Lymphoma, by Type
Table 17 : Global Market for Lymphoma in Blood Cancer Therapeutics, by Type, Through 2030
Table 18 : Global Market for Lymphoma in Blood Cancer Therapeutics, by Region, Through 2030
Table 19 : Global Market for Leukemia in Blood Cancer Therapeutics, by Type, Through 2030
Table 20 : Global Market for Leukemia in Blood Cancer Therapeutics, by Region, Through 2030
Table 21 : Global Market for Multiple Myeloma in Blood Cancer Therapeutics, by Region, Through 2030
Table 22 : Global Market for Rare Blood Cancers in Blood Cancer Therapeutics, by Region, Through 2030
Table 23 : Global Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
Table 24 : Few Approved Targeted Therapies in the Blood Cancer Therapeutics Market
Table 25 : Global Market for Targeted Therapy in Blood Cancer Therapeutics, by Region, Through 2030
Table 26 : Few Approved Immunotherapies in the Blood Cancer Therapeutics Market
Table 27 : Global Market for Immunotherapy in Blood Cancer Therapeutics, by Region, Through 2030
Table 28 : Approved Chemotherapies in the Blood Cancer Therapeutics Market
Table 29 : Global Market for Chemotherapy in Blood Cancer Therapeutics, by Region, Through 2030
Table 30 : Global Market for Blood Cancer Therapeutics, by Region, Through 2030
Table 31 : North American Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
Table 32 : North American Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
Table 33 : North American Market for Blood Cancer Therapeutics, by Country, Through 2030
Table 34 : Projected Number of New Blood Cancer Cases and Deaths by Sex in the U.S., 2026
Table 35 : U.S. Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
Table 36 : U.S. Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
Table 37 : Canadian Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
Table 38 : Canadian Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
Table 39 : Mexican Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
Table 40 : Mexican Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
Table 41 : European Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
Table 42 : European Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
Table 43 : European Market for Blood Cancer Therapeutics, by Country, Through 2030
Table 44 : German Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
Table 45 : German Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
Table 46 : U.K. Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
Table 47 : U.K. Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
Table 48 : French Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
Table 49 : French Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
Table 50 : Italian Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
Table 51 : Italian Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
Table 52 : Spanish Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
Table 53 : Spanish Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
Table 54 : Rest of Europe Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
Table 55 : Rest of Europe Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
Table 56 : Asia-Pacific Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
Table 57 : Asia-Pacific Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
Table 58 : Asia-Pacific Market for Blood Cancer Therapeutics, by Country, Through 2030
Table 59 : Japanese Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
Table 60 : Japanese Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
Table 61 : Chinese Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
Table 62 : Chinese Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
Table 63 : Indian Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
Table 64 : Indian Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
Table 65 : South Korean Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
Table 66 : South Korean Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
Table 67 : Australian Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
Table 68 : Australian Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
Table 69 : Rest of Asia-Pacific Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
Table 70 : Rest of Asia-Pacific Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
Table 71 : Middle East and African Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
Table 72 : Middle East and African Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
Table 73 : Middle East and African Market for Blood Cancer Therapeutics, by Region, Through 2030
Table 74 : Middle East Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
Table 75 : Middle East Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
Table 76 : African Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
Table 77 : African Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
Table 78 : South American Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
Table 79 : South American Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
Table 80 : South American Market for Blood Cancer Therapeutics, by Country, Through 2030
Table 81 : Brazilian Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
Table 82 : Brazilian Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
Table 83 : Argentine Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
Table 84 : Argentine Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
Table 85 : Rest of South America Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
Table 86 : Rest of South America Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
Table 87 : Key Strategic Initiatives, 2024-2026
Table 88 : Abbreviations Used in this Report
Table 89 : Report Sources
Table 90 : AbbVie Inc.: Company Snapshot
Table 91 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
Table 92 : AbbVie Inc.: Product Portfolio
Table 93 : AbbVie Inc.: News/Key Developments, 2023-2025
Table 94 : Amgen Inc.: Company Snapshot
Table 95 : Amgen Inc.: Financial Performance, FY 2023 and 2024
Table 96 : Amgen Inc.: Product Portfolio
Table 97 : Amgen Inc.: News/Key Developments, 2022-2026
Table 98 : Amneal Pharmaceuticals LLC.: Company Snapshot
Table 99 : Amneal Pharmaceuticals LLC.: Financial Performance, FY 2023 and 2024
Table 100 : Amneal Pharmaceuticals LLC.: Product Portfolio
Table 101 : Amneal Pharmaceuticals LLC.: News/Key Developments, 2025
Table 102 : AstraZeneca: Company Snapshot
Table 103 : AstraZeneca: Financial Performance, FY 2023 and 2024
Table 104 : AstraZeneca: Product Portfolio
Table 105 : AstraZeneca: News/Recent Developments, 2023-2025
Table 106 : Bristol-Myers Squibb Co.: Company Snapshot
Table 107 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
Table 108 : Bristol-Myers Squibb Co.: Product Portfolio
Table 109 : Bristol-Myers Squibb Co.: News/Key Developments, 2023-2026
Table 110 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 111 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 112 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 113 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023-2025
Table 114 : Gilead Sciences Inc.: Company Snapshot
Table 115 : Gilead Sciences Inc.: Financial Performance, FY 2023 and 2024
Table 116 : Gilead Sciences Inc.: Product Portfolio
Table 117 : Gilead Sciences Inc.: News/Key Developments, 2023-2025
Table 118 : GSK plc: Company Snapshot
Table 119 : GSK plc: Financial Performance, FY 2023 and 2024
Table 120 : GSK plc: Product Portfolio
Table 121 : GSK plc: News/Key Developments, 2025
Table 122 : Jazz Pharmaceuticals Inc.: Company Snapshot
Table 123 : Jazz Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
Table 124 : Jazz Pharmaceuticals Inc.: Product Portfolio
Table 125 : Jazz Pharmaceuticals Inc.: News/Key Developments, 2023
Table 126 : Johnson & Johnson: Company Snapshot
Table 127 : Johnson & Johnson: Financial Performance, FY 2023 and 2024
Table 128 : Johnson & Johnson: Product Portfolio
Table 129 : Johnson & Johnson: News/Key Developments, 2024-2026
Table 130 : Lilly USA LLC: Company Snapshot
Table 131 : Lilly USA LLC: Financial Performance, FY 2023 and 2024
Table 132 : Lilly USA LLC: Product Portfolio
Table 133 : Lilly USA LLC: News/Key Development, 2023-2025
Table 134 : Merck & Co. Inc.: Company Snapshot
Table 135 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
Table 136 : Merck & Co. Inc.: Product Portfolio
Table 137 : Merck & Co. Inc.: News/Key Developments, 2025
Table 138 : Novartis AG: Company Snapshot
Table 139 : Novartis AG: Financial Performance, FY 2023 and 2024
Table 140 : Novartis AG: Product Portfolio
Table 141 : Novartis AG: News/Key Developments, 2022-2024
Table 142 : Regeneron Pharmaceuticals Inc.: Company Snapshot
Table 143 : Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
Table 144 : Regeneron Pharmaceuticals Inc.: Product Portfolio
Table 145 : Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022-2025
Table 146 : Sanofi: Company Snapshot
Table 147 : Sanofi: Financial Performance, FY 2023 and 2024
Table 148 : Sanofi: Product Portfolio
Table 149 : Sanofi: News/Key Developments, 2022-2025
Table 150 : Few Emerging Companies in the Blood Cancer Therapeutics Market

List of Figures

Summary Figure : Global Market Shares of Blood Cancer Therapeutics, by Region, 2024
Figure 1 : Porter's Five Forces Analysis of the Blood Cancer Therapeutics Market
Figure 2 : Market Dynamics of Blood Cancer Therapeutics
Figure 3 : Companies' Expenditure, by Function, 2022
Figure 4 : Global Pharmaceutical R&D Spending and Growth, 2020-2026
Figure 5 : Global Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
Figure 6 : Global Market Shares of Lymphoma in Blood Cancer Therapeutics, by Region, 2024
Figure 7 : Global Market Shares of Leukemia in Blood Cancer Therapeutics, by Region, 2024
Figure 8 : Global Market Shares of Multiple Myeloma in Blood Cancer Therapeutics, by Region, 2024
Figure 9 : Global Market Shares of Rare Blood Cancers in Blood Cancer Therapeutics, by Region, 2024
Figure 10 : Global Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
Figure 11 : Global Market Shares of Targeted Therapy in Blood Cancer Therapeutics, by Region, 2024
Figure 12 : Global Market Shares of Immunotherapy in Blood Cancer Therapeutics, by Region, 2024
Figure 13 : Global Market Shares of Chemotherapy in Blood Cancer Therapeutics, by Region, 2024
Figure 14 : Global Market Shares of Blood Cancer Therapeutics, by Region, 2024
Figure 15 : North American Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
Figure 16 : North American Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
Figure 17 : North American Market Shares of Blood Cancer Therapeutics, by Country, 2024
Figure 18 : U.S. Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
Figure 19 : U.S. Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
Figure 20 : Canadian Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
Figure 21 : Canadian Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
Figure 22 : Mexican Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
Figure 23 : Mexican Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
Figure 24 : European Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
Figure 25 : European Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
Figure 26 : European Market Shares of Blood Cancer Therapeutics, by Country, 2024
Figure 27 : German Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
Figure 28 : German Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
Figure 29 : U.K. Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
Figure 30 : U.K. Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
Figure 31 : French Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
Figure 32 : French Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
Figure 33 : Italian Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
Figure 34 : Italian Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
Figure 35 : Spanish Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
Figure 36 : Spanish Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
Figure 37 : Rest of Europe Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
Figure 38 : Rest of Europe Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
Figure 39 : Asia-Pacific Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
Figure 40 : Asia-Pacific Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
Figure 41 : Asia-Pacific Market Shares of Blood Cancer Therapeutics, by Country, 2024
Figure 42 : Japanese Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
Figure 43 : Japanese Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
Figure 44 : Chinese Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
Figure 45 : Chinese Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
Figure 46 : Indian Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
Figure 47 : Indian Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
Figure 48 : South Korean Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
Figure 49 : South Korean Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
Figure 50 : Australian Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
Figure 51 : Australian Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
Figure 52 : Rest of Asia-Pacific Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
Figure 53 : Rest of Asia-Pacific Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
Figure 54 : Middle East and African Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
Figure 55 : Middle East and African Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
Figure 56 : Middle East and African Market Shares of Blood Cancer Therapeutics, by Region, 2024
Figure 57 : Middle East Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
Figure 58 : Middle East Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
Figure 59 : African Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
Figure 60 : African Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
Figure 61 : South American Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
Figure 62 : South American Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
Figure 63 : South American Market Shares of Blood Cancer Therapeutics, by Country, 2024
Figure 64 : Brazilian Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
Figure 65 : Brazilian Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
Figure 66 : Argentine Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
Figure 67 : Argentine Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
Figure 68 : Rest of South America Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
Figure 69 : Rest of South America Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
Figure 70 : Global Market Shares for Blood Cancer Therapeutics, by Company, 2024
Figure 71 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2024
Figure 72 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2024
Figure 73 : Amgen Inc.: Revenue Share, by Business Unit, FY 2024
Figure 74 : Amgen Inc.: Revenue Share, by Country/Region, FY 2024
Figure 75 : Amneal Pharmaceuticals LLC.: Revenue Share, by Business Unit, FY 2024
Figure 76 : AstraZeneca: Revenue Share, by Business Unit, FY 2024
Figure 77 : AstraZeneca: Revenue Share, by Country/Region, FY 2024
Figure 78 : Bristol-Myers Squibb Co.: Revenue Share, by Business Unit, FY 2024
Figure 79 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2024
Figure 80 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
Figure 81 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024
Figure 82 : Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2024
Figure 83 : Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2024
Figure 84 : GSK plc: Revenue Share, by Business Unit, FY 2024
Figure 85 : GSK plc: Revenue Share, by Country/Region, FY 2024
Figure 86 : Jazz Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2024
Figure 87 : Jazz Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2024
Figure 88 : Johnson & Johnson: Revenue Share, by Business Unit, FY 2024
Figure 89 : Johnson & Johnson: Revenue Share, by Country/Region, FY 2024
Figure 90 : Lilly USA LLC: Revenue Shares, by Business Unit, FY 2024
Figure 91 : Lilly USA LLC: Revenue Shares, by Country/Region, FY 2024
Figure 92 : Merck & Co. Inc.: Revenue Share, by Business Unit, FY 2024
Figure 93 : Merck & Co. Inc.: Revenue Share, by Country/Region, FY 2024
Figure 94 : Novartis AG: Revenue Shares, by Business Unit, FY 2024
Figure 95 : Novartis AG: Revenue Shares, by Country/Region, FY 2024
Figure 96 : Regeneron Pharmaceuticals Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 97 : Regeneron Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 98 : Sanofi: Revenue Share, by Country/Region, FY 2024

Blood Cancer Therapeutics: Global Markets to 2030

Description

Table of Contents

List of Tables

Report Scope

Report Includes

Table of Contents

Chapter 1 Executive Summary

Chapter 2 Market Overview

Chapter 3 Market Dynamics

Chapter 4 Regulatory Landscape

Chapter 5 Emerging Technologies and Pipeline Analysis

Chapter 6 Market Segmentation Analysis

Chapter 7 Competitive Intelligence

Chapter 8 Appendix

List of Tables

List of Figures